| MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases. | |
| | |
MedLine Citation:
|
PMID: 19051139 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cell therapy is fast emerging as a potential therapeutic option in cardiovascular therapeutics. Because of their inherent myogenic differentiation potential, skeletal myoblasts (SkMs) have been extensively assessed in preclinical and clinical studies for their feasibility, safety and effectiveness for myocardial repair. Bioheart Inc is developing MyoCell, autologous SkMs delivered by MyoCath and MyoStar catheter delivery systems, for the treatment of cardiovascular diseases such as myocardial infarction and congestive heart failure. MyoCell is undergoing phase II/III clinical development and has so far demonstrated safety and efficacy, including improvements in cardiac function in phase I/II clinical trials. |
| | |
Authors:
|
Husnain Kh Haider; Ye Lei; Muhammad Ashraf |
Related Documents
:
|
17762549 - Stem cell therapy for the treatment of heart failure. 16473959 - Mesenchymal stem cell injection after myocardial infarction improves myocardial complia... 18662809 - Orbital infarction in sickle cell disease. 16554359 - Activation of notch1 signaling in cardiogenic mesoderm induces abnormal heart morphogen... 17532949 - Reversible pulmonary trunk banding iii: assessment of myocardial adaptive mechanisms-co... 16315019 - Pathological findings in a patient with fabry disease who died after 2.5 years of enzym... 19332989 - Association of vegf gene polymorphisms with the development of heart failure in patient... 10976489 - Prenatal diagnosis of an aortico-left ventricular tunnel. 1343859 - Frontal signs following subcortical infarction. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Current opinion in molecular therapeutics Volume: 10 ISSN: 1464-8431 ISO Abbreviation: Curr. Opin. Mol. Ther. Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-12-03 Completed Date: 2009-02-04 Revised Date: 2013-06-04 |
Medline Journal Info:
|
Nlm Unique ID: 100891485 Medline TA: Curr Opin Mol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 611-21 Citation Subset: IM |
Affiliation:
|
University of Cincinnati, Department of Pathology and Laboratory Medicine, Cincinnati, OH 45267-0529, USA. haiderkh@ucmail.uc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cardiovascular Diseases
/
therapy* Cell Transplantation / methods Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Heart Failure / therapy Humans Myoblasts, Skeletal / metabolism, transplantation* Myocardial Infarction / therapy Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
HL-080686/HL/NHLBI NIH HHS; HL087246/HL/NHLBI NIH HHS; HL087288/HL/NHLBI NIH HHS; R01 HL087288-01A2/HL/NHLBI NIH HHS; R37-HL074272/HL/NHLBI NIH HHS |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Protein biomarkers in cancer: natural glycoprotein microarray approaches.
Next Document: Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervi...